During the last two CC's, Dr Scarlett has described imetelstat in the most clinical of terms. when he talkks about mechanism of action, it starts to become clear the advantage of the drug. If you have the scientific/medical expertise, you can read between the lines and see a very distinct advantage over the competitors.. It just took a while to zone in on hematological malignancies.
And remember, the largest potential patient population is the elderly who are too debilitated for bone marrow transplant surgery.
I'm not sellin'. See you in January for the pay off.
They are not talking CURE just modification!
"--- we believe imetelstat has the potential to be a disease-modifying treatment." ---This may be the key. The conclusion seems to be that this substance will have value in more than one situation.
Strange that the multiple ID, "fringe lunatic", Geron-negative, Bozo calling itself "hairypotter9" (today) can't make up its mind whether Geron is a "POS" (as this ID has described GERN regularly) or that a Geron "substance will have value in more than one situation".